Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.53 |
| ▸ | CA2 | P00918 | 8/20 | 0.53 |
| ▸ | HTR6 | P50406 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 6/20 | 0.52 |
| ▸ | CA12 | O43570 | 5/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7952397 | 0.98 | CA1 (0.55) | CA1CA2HTR6CA9CA12 | |
| SCHEMBL38652751 | 0.98 | CA1 (0.55) | CA1CA2HTR6CA9CA12 | |
| SCHEMBL4617638 | 0.84 | TSHR (0.53) | CA1CA2HTR6CA9CA12 | |
| SCHEMBL30437544 | 0.83 | PKM (0.55) | CA1CA2HTR6CA9CA12 | |
| SCHEMBL12719397 | 0.83 | HTR6 (0.70) | HTR6ALDH1A1LMNAKDM4E | |
| SCHEMBL8779983 | 0.83 | DRD2 (0.64) | HTR6ALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL16966426 | 0.82 | CA1 (0.48) | CA1CA2HTR6CA9CA12 | |
| SCHEMBL30437070 | 0.82 | GFER (0.49) | HTR6ALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL38652729 | 0.81 | HTR6 (0.54) | HTR6ALDH1A1MAPTLMNAKDM4E | |
| Hydrochloric Acid SCHEMBL28784493 | 0.81 | HTR6 (0.54) | HTR6ALDH1A1MAPTLMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718641-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718641-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-10968249-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200347092-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2020-11-05 | — | — | US | disclosed |
| US-10696713-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190194245-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2019-06-27 | — | — | US | disclosed |
| US-10208081-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20160185815-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160185815-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-20160176917-A1 | Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2016-06-23 | — | — | US | disclosed |
| US-20160176917-A1 | Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof | ENANTA PHARMACEUTICALS, INC. | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696713-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | CA1 2426/4885CA2 2269/4885HTR6 1825/4885 |
| US-10208081-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | CA1 2426/4885CA2 2269/4885HTR6 1825/4885 |
| US-20160185815-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | GPBAR1, NR1H4, SLC10A1 | CA1 2426/4885CA2 2269/4885HTR6 1825/4885 |
| US-20190194245-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | GPBAR1, NR1H4, SLC10A1 | CA1 2426/4885CA2 2269/4885HTR6 1825/4885 |
| US-20160176917-A1 | Bile Acid Derivatives as FXR/TGR5 Agonists and Methods of Use Thereof | GPBAR1, NR1H4, SLC10A1 | CA1 2426/4885CA2 2269/4885HTR6 1825/4885 |
| US-11718641-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | CA1 2426/4885CA2 2269/4885HTR6 1825/4885 |
| US-20200347092-A1 | BILE ACID DERIVATIVES AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF | GPBAR1, NR1H4, SLC10A1 | CA1 2426/4885CA2 2269/4885HTR6 1825/4885 |
| US-10968249-B2 | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof | GPBAR1, NR1H4, SLC10A1 | CA1 2426/4885CA2 2269/4885HTR6 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.